NasdaqGM:GMDA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Gamida Cell Ltd., a clinical stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Gamida Cell's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GMDA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.1%

GMDA

-2.7%

US Biotechs

-0.4%

US Market


1 Year Return

17.8%

GMDA

33.6%

US Biotechs

18.3%

US Market

Return vs Industry: GMDA underperformed the US Biotechs industry which returned 33.6% over the past year.

Return vs Market: GMDA matched the US Market which returned 18.3% over the past year.


Shareholder returns

GMDAIndustryMarket
7 Day-3.1%-2.7%-0.4%
30 Day32.2%2.7%6.6%
90 Day33.8%-3.0%8.6%
1 Year17.8%17.8%35.9%33.6%21.0%18.3%
3 Yearn/a20.0%13.9%42.1%32.7%
5 Yearn/a14.5%6.2%85.6%64.7%

Price Volatility Vs. Market

How volatile is Gamida Cell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Gamida Cell undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GMDA ($5.62) is trading below our estimate of fair value ($71.65)

Significantly Below Fair Value: GMDA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GMDA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GMDA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GMDA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GMDA is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Gamida Cell forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

52.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GMDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GMDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GMDA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GMDA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GMDA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Gamida Cell performed over the past 5 years?

-19.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GMDA is currently unprofitable.

Growing Profit Margin: GMDA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GMDA is unprofitable, and losses have increased over the past 5 years at a rate of 19.4% per year.

Accelerating Growth: Unable to compare GMDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GMDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: GMDA has a negative Return on Equity (-67.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Gamida Cell's financial position?


Financial Position Analysis

Short Term Liabilities: GMDA's short term assets ($90.9M) exceed its short term liabilities ($13.6M).

Long Term Liabilities: GMDA's short term assets ($90.9M) exceed its long term liabilities ($25.1M).


Debt to Equity History and Analysis

Debt Level: GMDA is debt free.

Reducing Debt: GMDA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GMDA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GMDA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Gamida Cell current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GMDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GMDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GMDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMDA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GMDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Julian Adams (65 yo)

2.92yrs

Tenure

US$2,232,000

Compensation

Dr. Julian Adams, Ph.D., serves as Executive Chairman of Elicio Therapeutics Inc. He serves as the Chief Executive Officer of Gamida Cell Ltd. since November 20, 2017. Dr. Adams was the President and Chief ...


CEO Compensation Analysis

Compensation vs Market: Julian's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD1.24M).

Compensation vs Earnings: Julian's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Julian Adams
CEO & Director2.92yrsUS$2.23mno data
Shai Lankry
Chief Financial Officer2.5yrsUS$843.00kno data
Ronit Simantov
Chief Medical Officer3.33yrsUS$912.00kno data
Joshua Hamermesh
Chief Business Officer2.5yrsUS$887.00kno data
Michele Korfin
Chief Operating & Chief Commercial Officer0.25yrno datano data
Tracey Lodie
Chief Scientific Officer1.33yrsno datano data
Jaren Madden
Vice President of Investor Relations & Corporate Communications2.25yrsno datano data
Paul Nee
Vice President of Marketing2.5yrsno datano data
Matthew Metivier
Vice President of Human Resource0.17yrno datano data
Naftali Brikashvili
Senior Vice President Finance & Operationsno datano datano data
Tzvi Palash
Chief Manufacturing Officer0.75yrno datano data
Jas Uppal
Chief Regulatory & Quality Officer0.75yrno datano data

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: GMDA's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Julian Adams
CEO & Director2.92yrsUS$2.23mno data
Kenneth Moch
Independent Director4.25yrsno datano data
Stephen Wills
Independent Director1.33yrsno datano data
David Fox
Independent Director0.25yrno datano data
Michael Perry
Independent Director3.42yrsno datano data
Nurit Benjamini
Independent Director1.75yrsno datano data
Robert Blum
Independent Chairman of the Board2.08yrsno datano data
Shawn Tomasello
Independent Director1.33yrsno datano data
Ofer Gonen
Independent Director5.75yrsno datano data

2.1yrs

Average Tenure

61yo

Average Age

Experienced Board: GMDA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.7%.


Top Shareholders

Company Information

Gamida Cell Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gamida Cell Ltd.
  • Ticker: GMDA
  • Exchange: NasdaqGM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$278.032m
  • Shares outstanding: 49.47m
  • Website: https://www.gamida-cell.com

Number of Employees


Location

  • Gamida Cell Ltd.
  • 5 Nahum Heftsadie Street
  • Givaat Shaul
  • Jerusalem
  • 91340
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GMDANasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDOct 2018

Biography

Gamida Cell Ltd., a clinical stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company’s lead product candidate is omidubicel, a nicotinamide ex ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 00:36
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.